

The Journal of Rheumatology

DEC 12 1991
HEALTH SCIENCES LIBRARY

VOLUME 18: NO. 11

NOVEMBER 1991

Editorials

- Challenges in Designing Antirheumatic Drug Trials**
C.H. Goldsmith 1643
- The Relationship of DM/PM to Malignancy**
J.P. Callen 1645
- What's Inside the Team Care Box? Is It the Parts, the Connections, the Attention, or the Gestalt?** *E.H. Yelin* 1647

Articles

- Phenotypic Abnormalities in CD8+ T Lymphocyte Subsets in Patients with RA**
S. Sohen, P.L. Romain, D.M. Rothstein, T. Yamane, S. Tanaka, P. Anderson, S.F. Schlossman, C. Morimoto 1649
- Prediction of Team Care Effects in Outpatients with RA**
M. Ahlmén, A. Bjelle, M. Sullivan 1655
- Prolactin Deficiency in RA**
E. Nagy, I.M. Chalmers, F.D. Baragar, H.G. Friesen, I. Berczi 1662
- An Immunohistochemical Study of the Collagens of Rabbit Synovial Interstitium**
D.E. Ashhurst, Y.S. Bland, J.R. Levick 1669
- Metabolism of Hydralazine by Activated Leukocytes: Implications for Hydralazine Induced Lupus**
A.H. Hofstra, L.C. Matassa, J.P. Uetrecht 1673
- Autoantibodies Against Ribosomal Proteins Found with High Frequency in Patients with SLE with Active Disease**
T. Sato, T. Uchiumi, T. Ozawa, M. Kikuchi, M. Nakano, R. Kominami, M. Arakawa 1681
- Sjögren's Syndrome in Patients with the CREST Variant of PSS** *A.A. Drosos, Y.L. Pennec, M. Elisaf, A. Lamour, N.C. Acritidis, J.R. Jouquan, H.M. Moutsopoulos, P. Youinou* 1685

- A Reexamination of the Relationship Between Myositis and Malignancy**
P. Schulman, L.D. Kerr, H. Spiera 1689
- MRI in the Idiopathic Inflammatory Myopathies**
D.D. Fraser, J.A. Frank, M. Dalakas, F.W. Miller, J.E. Hicks, P. Plotz 1693
- AS Antirheumatic Drug Trials. I. Effects of Standardization Procedures on Observer Dependent Outcome Measures**
N. Bellamy, W.W. Buchanan, J.M. Esdaile, A.G. Fam, W.F. Kean, J.M. Thompson, G.A. Wells, J. Campbell 1701
- AS Antirheumatic Drug Trials. II. Tables for Calculating Sample Size for Clinical Trials**
N. Bellamy, W.W. Buchanan, J.M. Esdaile, A.G. Fam, W.F. Kean, J.M. Thompson, G.A. Wells, J. Campbell 1709
- AS Antirheumatic Drug Trials. III. Setting the Delta for Clinical Trials of Antirheumatic Drugs — Results of a Consensus Development (Delphi) Exercise**
N. Bellamy, W.W. Buchanan, J.M. Esdaile, A.G. Fam, W.F. Kean, J.M. Thompson, G.A. Wells, J. Campbell 1716
- Pediatric Rheumatology**
- DNA Analysis of HLA-DR, DQ, and DP Genes in Pauciarticular JRA**
K.S. Barron, A.K. Joseph, M. Macleod, J.C. Gonzales, D. Owerback, J.D. Reveille 1723
- Hypercalcemia During the Resolution of Calcinosis Universalis in Juvenile DM**
B.E. Ostrov, D.P. Goldsmith, A.H. Eichenfield, B.H. Athreya 1730
- Barrett's Esophagus in a Young Patient with RP**
P. Navon, A. Klar, H. Hurvitz, S.N. Adler, D. Branski 1735

Contents continued opposite inside back cover . . .

PRINTED IN CANADA — ISSN 0315-162X

The Journal of Rheumatology

an international journal
founded by Metro A. Ogryzlo

EDITOR
Duncan A. Gordon

BOOK REVIEW EDITOR
Peter Lee

ASSOCIATE EDITORS
Dafna D. Gladman
Robert D. Inman
André Lussier
Waldemar Pruzanski
Earl D. Silverman
Hugh A. Smythe
Murray B. Urowitz

MANAGING EDITOR
Sonia Gruson

EDITORIAL ASSISTANT
Yvonne Pigott

ADVERTISING MANAGER
Michelle Garneau

MANUSCRIPT MANAGER
Carlyle Rodrigo

SUBSCRIPTIONS
Domenica Lagana

ADMINISTRATIVE SECRETARY
Deborah Wood

EDITORIAL BOARD

Donato Alarcón-Segovia
MEXICO CITY, MEXICO

Roberto Arinovich Schenker
SANTIAGO, CHILE

Frank C. Arnett
HOUSTON, TX, USA

Eugene V. Barnett
LOS ANGELES, CA, USA

John Baum
ROCHESTER, NY, USA

Kenneth D. Brandt
INDIANAPOLIS, IN, USA

David A. Bell
LONDON, ON, CANADA

Anders Bjelle
GOTHENBURG, SWEDEN

John Bland
BURLINGTON, VT, USA

Barry Bresnihan
DUBLIN, IRELAND

Irvin Broder
TORONTO, ON, CANADA

W. Watson Buchanan
HAMILTON, ON, CANADA

Gerd R. Burmester
ERLANGEN, FRG

Juan J. Canoso
BOSTON, MA, USA

David E. Caughey
AUCKLAND, NEW ZEALAND

T. Derek V. Cooke
KINGSTON, ON, CANADA

George E. Ehrlich
PHILADELPHIA, PA, USA

Adel G. Fam
TORONTO, ON, CANADA

Irving H. Fox
CAMBRIDGE, MA, USA

Antonio Fraga
MEXICO CITY, MEXICO

James F. Fries
STANFORD, CA, USA

Marvin J. Fritzler
CALGARY, AB, CANADA

J. Philip Gofton
VANCOUVER, BC, CANADA

Charles H. Goldsmith
HAMILTON, ON, CANADA

Bevra Hahn
LOS ANGELES, CA, USA

Peter Hasselbacher
LOUISVILLE, KY, USA

David E. Hastings
TORONTO, ON, CANADA

Marc C. Hochberg
BALTIMORE, MD, USA

Mitsuo Homma
TOKYO, JAPAN

Graham R. V. Hughes
LONDON, ENGLAND

Gene C. Hunder
ROCHESTER, MN, USA

Gunnar Husby
TROMSØ, NORWAY

Marcel-Francis Kahn
PARIS, FRANCE

Edward C. Keystone
TORONTO, ON, CANADA

John H. Klippel
BETHESDA, MD, USA

J.T. Lie
ROCHESTER, MN, USA

Peter E. Lipsky
DALLAS, TX, USA

Geoffrey O. Littlejohn
CLAYTON, AUSTRALIA

Alphonse T. Masi
PEORIA, IL, USA

Gale A. McCarty
OKLAHOMA CITY, OK, USA

Frederick C. McDuffie
ATLANTA, GA, USA

Henri Ménard
SHERBROOKE, PQ, CANADA

John Mills
BOSTON, MA, USA

Alastair G. Mowat
HEADINGTON, OXFORD, ENGLAND

Kenneth D. Muirden
MELBOURNE, AUSTRALIA

C. Kirk Osterland
MONTREAL, PQ, CANADA

Gabriel S. Panayi
LONDON, ENGLAND

Ross E. Petty
VANCOUVER, BC, CANADA

Theodore Pincus
NASHVILLE, TN, USA

Kenneth P. H. Pritzker
TORONTO, ON, CANADA

Donald Resnick
SAN DIEGO, CA, USA

Naomi Rothfield
FARMINGTON, CT, USA

Anthony S. Russell
EDMONTON, AB, CANADA

H. Ralph Schumacher, Jr.
PHILADELPHIA, PA, USA

Alan J. Silman
MANCHESTER, ENGLAND

Virginia D. Steen
PITTSBURGH, PA, USA

Eric M. Veys
GHENT, BELGIUM

Michael E. Weinblatt
BOSTON, MA, USA

Arthur Weinstein
VALHALLA, NY, USA

Keith Whaley
GLASGOW, SCOTLAND

Frederick Wolfe
WICHITA, KS, USA

Verna Wright
LEEDS, ENGLAND

Copyright 1991.
All rights reserved.®
Microforms available from
University Microfilms,
300 N. Zeeb Rd.,
Ann Arbor, MI 48106 USA.

The Journal of Rheumatology (ISSN 0315-162X) is published monthly for
\$120.00 per year by the Journal of Rheumatology Publishing Co. Ltd.
920 Yonge St., Ste. 115, Toronto, Ont. M4W 3C7
SECOND CLASS POSTAGE USPS 737-930 AT BUFFALO, N.Y.
Postmaster send address changes to
Journal of Rheumatology, 1051 Clinton St., Buffalo, N.Y. 14206.

Humanized Monoclonal Antibody Treatment in Rheumatoid Arthritis

VALERIE KYLE, JANET RODDY, GEOFFREY HALE, BRIAN L. HAZLEMAN, and HERMAN WALDMANN

Abstract. A 41-year-old woman with active, seropositive erosive rheumatoid arthritis was treated with the humanized monoclonal antibody Campath 1H. She had not responded or developed side effects to myocrisin, sulfasalazine and penicillamine, and had not responded to inpatient bedrest and physiotherapy. There was a rapid clinical improvement within 24 hours of infusion, which was maintained for about 12–14 weeks after the infusion. The lymphocyte count was suppressed for 7 months after treatment. There were no significant side effects during or after treatment. No anti-Campath 1H response was detected. This preliminary study suggests humanized monoclonal antibody therapy may be of value in the treatment of rheumatoid arthritis. (*J Rheumatol* 1991;18:1737–8)

Key Indexing Terms:

RHEUMATOID ARTHRITIS

HUMANIZED MONOCLONAL ANTIBODIES

THERAPEUTICS

Monoclonal antibody (Mab) therapy in rheumatoid arthritis (RA) allows the targeting of specific cells or effector mechanisms believed to be important in the pathogenesis. Initial pilot studies using rat^{1,2} and mouse³ Mab have shown some benefit, though there has been concern that the development of human antimouse Mab may prevent retreatment^{3–5}. This concern has been due to the risk of sensitization, and evidence suggests repeat infusions may be less effective. The development of humanized Mab⁶ should minimize this risk. We report the beneficial effect of Campath 1H, a humanized Mab, against surface antigen CDW52 in a patient with RA.

Campath 1H is the humanized form of the rat Mab produced by fusion of the Y3 rat myeloma line with a spleen from a rat immunized with human T lymphocytes. The hypervariable regions of this rat antibody are then transplanted into normal human immunoglobulin (Ig) genes.

The Campath 1 antigen is present on the majority of, if not all, lymphocytes and monocytes⁷.

CASE REPORT

A 41-year-old woman with active erosive RA for 6 years was admitted for treatment with Campath 1H. Written consent and ethical approval were

obtained. She had not responded or had developed side effects to sulfasalazine, gold or penicillamine, and was taking naproxen only. At the time of the study she had persistent synovitis affecting most joints, with morning stiffness for 2 h, and had failed to improve after a period of inpatient bedrest and physiotherapy.

Twelve infusions of 2 mg Campath 1H in 500 ml normal saline were given over 4 h on Days 1 through 12. Pulse, blood pressure and temperature were recorded at 15-min intervals during the infusion, then every 2 h for 4 h afterwards. Her functional score was derived from the pain scores, sense of wellbeing and ability to cope with daily activities. These were all measured using a visual analog scale, 0 being normal and 10 maximal discomfort. Ritchie index, grip strength, and thermal index derived from thermography were recorded daily during infusions and every 2–4 weeks for 4 months afterwards. The following laboratory tests were performed before treatment, daily during infusions and regularly in followup: full blood count including differential white cell count, erythrocyte sedimentation rate (ESR) (Westergren), C-reactive protein (CRP) (nephelometry) and rheumatoid factor (RF) (nephelometry). Ig, CD4 and CD8 levels, urea and electrolytes were measured and liver tests administered before and after treatment.

There were no significant side effects. There were no febrile episodes or cardiovascular effects during the Campath 1H infusion or over the subsequent 4 h. There was rapid clinical improvement, with a fall in Ritchie index from 26 to 9, a fall in functional score from 19.5 to 5.25, and a rise in grip strength (Figure 1). Morning stiffness decreased to 30 min and the thermal index fell. Functionally she was able to knit, walk more than 1 mile and sleep comfortably in any position for the first time in over a year. This improvement in function was maintained for about 12–14 weeks. Her symptoms were controlled with naproxen alone during this time. Laboratory data showed that the total lymphocyte count became undetectable after the second infusion. At 6 months posttreatment the lymphocyte count was still slightly below normal ($1.05 \times 10^9/l$) and the suppression involved all T cell subsets, but the B lymphocyte count was normal. The total lymphocyte count returned to normal 7 months after treatment. During this time there was no clinical evidence of immunosuppression. The monocyte count had fallen from normal ($0.415 \times 10^9/l$) to zero 2 days into treatment. One month after the final infusion it had returned to normal. RF fell within 2 days to 1/3 of the initial value and rose after 8 weeks to baseline levels. There was no significant change in ESR or CRP (Figures 2a and 2b).

From the Rheumatology Research Unit and Division of Rheumatology Addenbrooke's Hospital, Cambridge, United Kingdom.

V. Kyle, MD, MRCP, Lecturer in Rheumatology; J. Roddy, MD, FRCP, Clinical Research Fellow in Rheumatology, Rheumatology Research Unit; G. Hale, PhD, Director of Therapeutic Antibody Unit; B.L. Hazleman, MB, FRCP, Consultant Rheumatologist, Rheumatology Research Unit, Addenbrooke's Hospital; H. Waldmann, PhD, MRCP, Professor of Therapeutic Immunology, Department of Pathology.

Address reprints requests to Dr. B.L. Hazleman, Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom.

Submitted December 31, 1990 revision accepted July 10, 1991.




Fig. 1. Clinical course in patient receiving Campath 1H. Infusions were given on Days 1-12. The Ritche index is used to assess joint inflammation. Grip strength \blacktriangle , L \blacksquare ; functional score \bullet ; Ritche index \circ .




Fig. 2a. Laboratory variables in patient receiving Campath 1H. Total white blood cell count \triangle , lymphocytes \diamond , ESR \blacksquare .




Fig. 2b. Laboratory variables in patient receiving Campath 1H. CRP \blacksquare , RF \triangle .

No anti-Campath 1H response was detected. Ig levels before and after treatment were unchanged, with a polyclonal increase in IgA and IgG but normal IgM.

DISCUSSION

Earlier studies using lymphopheresis or T cell irradiation resulted in short term benefit in patients with RA. More recently, studies have shown benefit from treatment with Mab^{8,9}. Campath 1H infusions caused destruction or removal of T lymphocytes from peripheral blood and were followed by sustained clinical benefit for 3 months. The fall in RF probably reflects loss of T cell cooperation in stimulating B cell production of RF. It is interesting that neither ESR nor CRP fell significantly despite the marked clinical improvement; this may have been due to established inflammation that was unaffected by T cell removal.

The development of humanized Mab such as Campath 1H should allow repeated infusions without the risk of sensitization or decreasing efficacy. No antibodies to Campath 1H were detected. There were no serious side effects following Campath 1H in our study or reported during treatment of patients with lymphatic malignancies¹⁰. Although lymphopenia can predispose to viral or fungal infections, this was not a problem in our patient.

Further studies of humanized Mab are warranted.

REFERENCES

1. Mathieson W, Cobbold P, Hale C, *et al*: Monoclonal antibody therapy in systemic vasculitis. *N Engl J Med* 1990;323:250-4.
2. Kyle V, Coughlan RJ, Tighe H, Waldmann H, Hazleman BL: Beneficial effect of monoclonal antibody to interleukin 2 receptors on activated T cells in rheumatoid arthritis. *Ann Rheum Dis* 1989;48:428-9.
3. Strand V, Fishwild D: XOMA Rheumatoid arthritis investigators group. Treatment of rheumatoid arthritis with anti-CD5 immunoconjugate: clinical and immunologic findings and preliminary results of re-treatment (abstr). *Arthritis Rheum* 1990;(suppl)33:S25.
4. Horneff G, Winkler T, Kalden J, Emmrich F, Bermester GR: Human anti-mouse antibody response induced by anti-CD4 monoclonal antibody therapy in patients with rheumatoid arthritis. *Clinical Immunol Immunopathol* 1991;59:89-103.
5. Wassmer P, Neidhart M, Hintermann U, *et al*: Therapy of rheumatoid arthritis with CD4 monoclonal antibodies (abstr). *Arthritis Rheum* 1990;(suppl)33:S153.
6. Reichmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. *Nature* 1988;332:323-7.
7. Hale G, Xia M-Q, Tighe HP, Dyer MJS, Waldman H: The Campath-1 antigen (CDW52). *Tissue Antigens* 1990;35:118-27.
8. Kingsley G: Monoclonal antibody treatment of rheumatoid arthritis. *Br J Rheumatol* 1991;(suppl 2)30:33-5.
9. Horneff G, Bermester G, Emmrich F, Kalden J: Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. *Arthritis Rheum* 1991;34:129-40.
10. Hale G, Cobbold S, Waldmann H: T cell depletion with Campath-1H in allogeneic bone marrow transplantation. *Transplantation* 1988;45:753-9.

The Journal of Rheumatology

Guide for Authors Submitting Manuscripts

Manuscripts for publication and all other editorial communications should be mailed to the Editor, The Journal of Rheumatology, 920 Yonge St., Ste. 115, Toronto, Ont. M4W 3C7. Articles, editorials, hypotheses, reviews, case reports of exceptional interest and letters will be accepted for publication on condition that they are submitted solely to this *Journal*. Subject matter may relate to the broad field of rheumatology, rehabilitation medicine, immunology, infectious diseases or orthopaedic subjects pertaining to the rheumatic diseases.

Manuscripts should be concise and typed double-spaced on one side of good quality paper, with liberal margins. Please note that journal titles cited in the references should conform to the abbreviations used in *Index Medicus* and should follow the style shown below.

Provide an original, and 3 copies *each* of manuscript and tables. Submit 4 glossy prints of each figure. Xerographic copies are *not* acceptable. Number each page, including tables and figure legends, in sequence. Submit an abstract of no more than 100 words as part of the title page of the manuscript. Organize the manuscript to include: Title Page, Introduction, *Materials and Methods*, *Results*, *Discussion*, *Acknowledgment*, *References*, Tables, Figures and Figure Legends. Indicate the main sections noted in italics by side headings. Use the Arabic numbering system throughout the manuscript except at the beginning of sentences. Check manuscripts carefully before submission. To aid in the review of the manuscript, include the statistical worksheet (not for publication), if applicable. Because of increasing publication costs, present the message as concisely as possible. For example, the *Discussion* should not exceed half the length of the whole article (preferably a third). Authors are welcome to suggest the names of 3 or 4 persons who might be considered suitable reviewers of their work.

Case Reports should contain no more than 1000 words but authors may submit a description of the clinical findings and the course of their cases under the general heading of *Case Report* in place of the *Materials and Methods* and *Results* sections. They should contain no more than 3 figures or tables and no more than 15 references.

Editorial comment in the form of a Letter to the Editor is invited; however, it should not exceed 800 words. Letters may include 10 references but no more than 2 figures or tables and no subdivision for an Abstract, Methods or Results. Full name(s) and academic appointment(s) of the author(s) should accompany any letter.

Supplements. The *Journal* welcomes the opportunity to publish proceedings of significant symposia providing the material represents original work not previously published.

Symposium organizers are urged to contact the editor well in advance of the symposium date with a draft program. Faculty, subject matter and editorial content are all subject to the approval of the editorial committee. Papers submitted to be published in the proceedings must conform to the style outlined in this guide before they will be considered for publication.

Details of Format and Organization

Title Page. Title page should be separate and have in the following order:

- Full title of manuscript which should be concise but informative;
- Given and surname of author(s) without degrees;
- Abstract (no more than 100 words);
- Key Indexing Terms—a list of no more than 6 terms;
- Name of department(s) and institution(s) to which the work should be attributed;
- The source(s) of support in the form of grants and industrial support;
- Initials, surnames, appointments and highest academic degrees of *all authors*;
- Name and address of author to whom requests for reprints should be made;
- Name and address of author responsible for correspondence about the manuscript;
- A short running head or footline of no more than 50 words;

Acknowledgment, if applicable, should be added at the end of the discussion of the paper and before the references. It should not contain grant or industrial support for fellowships or awards, all of which should appear on the title page.

Tables. Type each table on a separate sheet, double-spaced. Number tables consecutively and supply a brief title for each. References cited only in tables should be numbered in the sequence established by identification in the text.

Figures. These should be numbered with the author's name on the back and the top clearly marked. Legends should be listed on a separate sheet. Figures should be professionally drawn and photographed and the critical area of radiograph or photomicrographs should be indicated. Freehand or typewritten lettering is unacceptable. Send sharp glossy black and white photographic prints no larger than 12.8 × 18 cm (5 × 7"). Cite each figure in the text in consecutive order. The contributor must bear all the costs of colour printing.

References. Number references consecutively in the order in which they are mentioned in the text. Identify references

SEE PAGE